Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
---|
02/22/1996 | WO1996005254A1 Starch-bound cellular matrix |
02/22/1996 | WO1996005218A1 Delivery of nucleic acids |
02/22/1996 | WO1996005212A1 Water-soluble polyene conjugate |
02/22/1996 | WO1996004932A1 Novel vaccine adjuvant and vaccine |
02/22/1996 | WO1996004931A1 Peroral immunogen composition and process for producing the same |
02/22/1996 | WO1996004927A1 NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL COMPOSITIONS THEREOF |
02/22/1996 | WO1996004925A1 Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
02/22/1996 | WO1996004924A1 Improved antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
02/22/1996 | WO1996004902A1 Composition of external preparation |
02/22/1996 | WO1996004890A1 Vesicle formulation |
02/22/1996 | WO1996004889A1 Process for preparing beclomethasone dipropionate freon® clathrate |
02/22/1996 | WO1995034665A3 Chimerical peptide-nucleic acid fragment, process for producing the same and its use for appropriately introducing nucleic acids into cell organelles and cells |
02/22/1996 | DE4429667A1 Estradiol-TTS mit wasserbindenden Zusätzen Estradiol-TTS with water-binding additives |
02/22/1996 | DE4429664A1 Estradiol-TTS mit wasserbindenden Zusätzen Estradiol-TTS with water-binding additives |
02/22/1996 | DE4428986A1 New alprazolam formulation with improved release kinetics |
02/22/1996 | DE4418691A1 3'-(4'-) nicht-radioaktiv markierte Nukleoside und Nukleotide mit Aminocarbonsäure-, Peptid- oder Carbonsäure-Spacer 3 '- (4') non-radioactively labeled nucleosides and nucleotides with aminocarboxylic acid, peptide or carboxylic acid-spacer |
02/22/1996 | DE19530509A1 Prepn. of solid, stomach-acid resistant pharmaceutical prepns. |
02/22/1996 | CA2197059A1 Starch-bound cellular matrix |
02/22/1996 | CA2196415A1 Peroral immunogen composition and process for producing the same |
02/22/1996 | CA2196171A1 Process for preparing beclomethasone dipropionate freon? clathrate |
02/22/1996 | CA2173727A1 Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof |
02/21/1996 | EP0697218A2 Method of preparing cross-linked biomaterial compositions for use in tissue augmentation |
02/21/1996 | EP0696921A1 Veterinary composition containing a proton pump inhibitor |
02/21/1996 | EP0696920A1 Improved pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug |
02/21/1996 | EP0696918A1 Composition containing cholestyramine and method of producing the same |
02/21/1996 | CN1117266A Stable protein: phospholipid compositions and methods |
02/21/1996 | CN1116926A Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract |
02/21/1996 | CN1116903A Lipid vesicles and aqueous emulsions containing thom, and to a process for producing them |
02/21/1996 | CN1031038C Prolonged release of biologically active polyepeptides |
02/21/1996 | CN1031036C Multi-layer granule |
02/20/1996 | US5493017 Ring-metalated porphyrins |
02/20/1996 | US5492938 Pharmaceutical composition and dietary supplement containing docosarexaenoic acid obtained from dinoflagellates |
02/20/1996 | US5492937 Gel-forming liquid carrier composition |
02/20/1996 | US5492893 Sterilization of animals; therapy od sex hormone relateddiseases |
02/20/1996 | US5492821 Diagnostics, food industry |
02/20/1996 | US5492809 Mutations rendering platelet glycoprotein Ib-α less reactive |
02/20/1996 | US5492701 Atomizing oil in water emulsion containing vitamin a acetate or vitamin e, allowing the spherules formed to fall through countercurrent cold air flow(in tower) into liquid crosslinking agent, then recovering hardened spherules |
02/20/1996 | US5492698 Lanoline derivatives as penetration enhancing substances |
02/20/1996 | CA1338079C Adhesion protein micelles |
02/20/1996 | CA1338074C Low-viscosity pressure-adherent silicone elastomer compositions |
02/15/1996 | WO1996004340A1 Conducting electroactive biomaterials |
02/15/1996 | WO1996004313A1 Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
02/15/1996 | WO1996004311A1 Monoclonal antibody to nitrotyrosine, methods for diagnosis and methods for treatment of disease |
02/15/1996 | WO1996004302A1 Novel tumor marker for lung cancer |
02/15/1996 | WO1996004017A1 Iron-containing nanoparticles with double coating and their use in diagnosis and therapy |
02/15/1996 | WO1996004016A1 Conjugates of vitamin b12 and proteins |
02/15/1996 | WO1996004001A1 Site-specific biomolecular complexes |
02/15/1996 | WO1996003984A1 Controlled local delivery of chemotherapeutic agents for treating solid tumors |
02/15/1996 | WO1996003978A1 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
02/15/1996 | WO1996003973A1 Highly bioadhesive and mucoadhesive compositions for the treatmenof epithelia and mucous membranes |
02/15/1996 | WO1996003875A1 Compositions for targeting materials to cells containing androgen receptors |
02/15/1996 | WO1995019169A3 Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor |
02/15/1996 | CA2197770A1 Compositions for targeting materials to cells containing androgen receptors |
02/15/1996 | CA2196562A1 Highly bioadhesive and mucoadhesive compositions for the treatment of epithelia and mucous membranes |
02/15/1996 | CA2195566A1 Conjugates of vitamin b12 and proteins |
02/14/1996 | EP0696617A2 Method of controlling structure stability of collagen fibers produced from solutions or dispersions treated with sodium hydroxide for infectious agent deactivation |
02/14/1996 | EP0696598A1 Polysaccharide esters and their salts |
02/14/1996 | EP0696270A1 4-amino-fluorobenzamides and their use as cytotoxic prodrugs |
02/14/1996 | EP0696208A1 Oral drug delivery compositions and methods |
02/14/1996 | EP0696201A1 Supplemented and unsupplemented tissue sealants, methods of their production and use |
02/14/1996 | EP0696200A1 Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression |
02/14/1996 | EP0696192A1 Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof |
02/14/1996 | EP0696191A1 Particulate vector and pharmaceutical composition containing such vector |
02/14/1996 | CN1116629A Monomeric insulin analog formulations |
02/14/1996 | CN1116525A 透皮吸收制剂 Transdermal preparations |
02/14/1996 | CN1116523A Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract |
02/14/1996 | CN1116522A Stable freeze-dried formulation comprising a protein assay kit |
02/14/1996 | CN1116521A Sustained release compositions and a method of preparing pharmaceutical compositions |
02/14/1996 | CN1030964C Task-masking composition of bitter pharmaceutical agents |
02/13/1996 | US5491171 Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration |
02/13/1996 | US5491154 A premixes of nimodipine, citric acid, sodium bicarbonate, citrus flavor and organe granules; solubility |
02/13/1996 | US5491088 Genetic engineering |
02/13/1996 | US5490991 Directed delivery of radioprotectants using a receptor specific carrier |
02/13/1996 | US5490990 Production of solid pharmaceutical depot forms |
02/13/1996 | US5490988 Delivery of therapeutic agents to a target site |
02/13/1996 | US5490987 Tableting of colestipol hydrochloride |
02/13/1996 | US5490984 Injecting wound healing agents into defective area |
02/13/1996 | US5490980 Transglutaminase crosslinks proteins by catalyzing the active ingrediants to glutamine residues |
02/13/1996 | CA2090422C Pharmaceutical composition of florfenicol |
02/13/1996 | CA2035841C Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture |
02/08/1996 | WO1996003653A1 Superparamagnetic particles, process for their production and their use |
02/08/1996 | WO1996003649A1 Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME |
02/08/1996 | WO1996003517A1 Process for preparing viruses and viral vectors |
02/08/1996 | WO1996003515A2 Surface expression of enzyme in gene directed prodrug therapy |
02/08/1996 | WO1996003502A2 Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer |
02/08/1996 | WO1996003151A2 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
02/08/1996 | WO1996003147A1 Synthesis of chemical gels from polyelectrolyte polysaccharides by gamma-irradiation |
02/08/1996 | WO1996003142A1 Drug delivery composition for the nasal administration of antiviral agents |
02/08/1996 | WO1996003131A1 Percutaneously absorbable preparation |
02/08/1996 | WO1996003117A1 Incorporation of biologically active molecules into bioactive glasses |
02/08/1996 | WO1996003116A1 Controlled release of metal cation-stabilized interferon |
02/08/1996 | WO1996003114A1 Lock and key micelles |
02/08/1996 | WO1996003113A1 Self-emulsifying drug delivery system |
02/08/1996 | WO1996003112A1 Compositions comprising a tissue glue and therapeutic agents |
02/08/1996 | WO1995022611A3 Methods and compositions for stimulating bone cells |
02/08/1996 | DE4428851A1 Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie Iron-containing nanoparticles, their preparation and use in the diagnosis and treatment |
02/08/1996 | DE4418936A1 Polypeptid Polypeptide |
02/08/1996 | CA2196052A1 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
02/08/1996 | CA2196051A1 Surface expression of enzyme in gene directed prodrug therapy |
02/08/1996 | CA2195994A1 Controlled release of metal cation-stabilized interferon |